Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 119 publications.

Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, Odak S, Jackson L, Beyhagh H, Toback S. Reactogenicity differences between adjuvanted, protein-based and messenger ribonucleic acid (mRNA)-based COVID-19 vaccines. Vaccines (Basel). 2024 Jul 19;12(7):802. doi: 10.3390/vaccines12070802

Bonner C, Pilar M, Jacobs S, Samsell B, Hollis K. Optimizing drug value and access using implementation science. Poster presented at the ISPOR 2024; May 7, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S318. doi: 10.1016/j.jval.2024.03.2000

Rousculp MD, Hollis K, Ziemiecki R, Odom D, Marchese AM, Montazeri M, Odak S, Jackson L, Miller A, Toback S. Burden and impact of reactogenicity among adults receiving COVID-19 vaccines in the United States and Canada: results from a prospective observational study. Vaccines (Basel). 2024 Jan 13;12(1):83. doi: 10.3390/vaccines12010083

Calhoun S, Kutikova L, Hollis KA, Helme K, Miller A, Schwarz TF. A novel approach to capturing real-world reasons behind use and satisfaction of NVX-CoV2373 booster use among German adults: direct-to-patient enrollment. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S490. doi: 10.1016/j.jval.2023.09.2649

Toback S, Hollis K, Beyhaghi H, Ziemiecki R, Odom D, Choi JM, Layton JB, Odak S, Jackson L, Williams V, Marchese AM, Milller A, Rousculp M. Presenteeism: the reality to be discussed with COVID-19 vaccine recipients. Poster presented at the European Scientific Working Group on Influenza (ESWI); September 17, 2023. Valencia, Spain.

Rousculp M, Beyhaghi H, Hollis K, Ziemiecki R, Layton JB, Odak S, Jackson L, Odom D, Williams V, Choi JM, Montazeri M, Marchese AM, Toback S. Burden and impact of reactogenicity among United States and Canadian adults receiving COVID-19 vaccines: Vaccine Impact on Productivity (VIP) Study. Poster presented at the European Scientific Working Group on Influenza (ESWI); September 17, 2023. Valencia, Spain.

Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7

Richardson D, Zhan L, Reynolds M, Odom D, Hollis K, Mitra D, McRoy L, Hargis J. The impact of advanced or metastatic breast cancer or its treatment on productivity, energy, and physical activity among palbociclib participants of the MADELINE Study. Poster presented at the Virtual 12th European Breast Cancer Conference; October 2, 2020.

Banerji A, Davis KH, Brown TM, Hollis K, Hunter SM, Long J, Jain G, Devercelli G. Patient-reported burden of hereditary angioedema: findings from a patient survey in the United States. Ann Allergy Asthma Immunol. 2020 Jun;124(6):600-7. doi: 10.1016/j.anai.2020.02.018

Richardson D, Zhan L, Reynolds M, Odom D, Hollis K, Mitra D, McRoy L, Jones C, Mahtani R, Hargis J. The effect of neutropenia on patient-reported functioning and Quality of Life (QOL) among palbociclib participants of the MADELINE Study. Poster presented at the 2020 ASCO Virtual Scientific Program; June 2020. [abstract] J Clin Oncol. 2020 Jun; 38(2020):1064. doi: 10.1200/JCO.2020.38.15_suppl.1064

Reynolds M, Odom D, Richardson D, Hollis KA, Zhan L, Mitra D, McRoy L, Bowles S. Benefits and challenges of mobile health applications in prospective studies: learnings from the Madeline Study and literature. Poster presented at the 2020 ISPOR Virtual Conference; May 2020. [abstract] Value Health. 2020 May 1; 23(Suppl 1):S71-2. doi: 10.1016/j.jval.2020.04.1183

Richardson D, Zhan L, Reynolds M, Hollis K, McRoy L, Mitra D, Mahtani R. Trends in daily mood, pain, and fatigue among participants in the MADELINE study. Poster presented at the 2019 San Antonio Breast Cancer Symposium; December 11, 2019. San Antonio, TX.

Sacco P, Myers K, Poulos C, Sweeney C, Hollis K, Snow V, Vietri JT. Preferences for adult pneumococcal vaccine recommendations among United States health care providers. Infect Dis Ther. 2019 Dec;8(4):657-70. doi: 10.1007/s40121-019-00266-5

Radawski C, Genovese MC, Hauber B, Nowell WB, Hollis K, Gaich CL, DeLozier AM, Gavigan K, Reynolds M, Cardoso A, Curtis JR. Patient perceptions of unmet medical need in rheumatoid arthritis: a cross-sectional survey in the USA. Rheum Ther. 2019 Sep;6(3):461-71. doi: 10.1007/s40744-019-00168-5

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport E, Hollis KA, Djokanovic N, Racanelli VS, Petraro P, Vassilev ZP. Evaluation of physician knowledge of the key safety information for aflibercept in Canada: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):235-46. doi: 10.1007/s40290-019-00278-z

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Schmidt-Ott UM, Petraro P, Vassilev ZP. Physician and patient knowledge of safety and safe use information for aflibercept in Europe: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):219-33. doi: 10.1007/s40290-019-00279-y

Richardson D, Mitra D, Hollis K, Reynolds M, Odom D, Kaye JA, Zhan L, McRoy L. A prospective, observational study of mobile application-based patient-reported outcomes in advanced breast cancer: select patient-reported interim data from the MADELINE study. Poster presented at the 36th Annual Miami Breast Cancer Conference; March 2019. Miami, FL.

Lacour JP, Khemis A, Giordano-Labadie F, Martin Lu, Staumont-Salle D, Hacard F, Tian H, McBride D, Hollis K, Hunter S, Martin L, Lamirand A, Le Guen S, Balp MM, Berard F. The burden of chronic spontaneous urticaria: unsatisfactory treatment and healthcare resource utilization in France (the ASSURE-CSU study). Eur J Dermatol. 2018 Dec 1. doi: 10.1684/ejd.2018.3446

Mordin M, Castro C, Buck PM, Fernandez MM, Hollis KA, Ritchey ME. European “real-world” evidence for drugs and devices: 2017 literature reviewed. Poster presented at the 2018 ISPOR 21st Annual European Congress; November 13, 2018. Barcelona, Spain.

Andreas S, Chouaid C, Danson S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Chirila C, Hollis K, Sweeney C, Price M, Wolowacz S, Kaye JA, Kontoudis I. Economic burden of resected (stage IB-IIIA) non-small cell lung cancer in France, Germany and the United Kingdom: a retrospective observational study (LuCaBIS). Lung Cancer. 2018 Oct;124:298-309. doi: 10.1016/j.lungcan.2018.06.007

Odom D, Mitra D, Hollis K, Richardson D, Kaye J, McRoy L. A prospective observational study of mobile application-based Patient-Reported Outcomes (PRO) in advanced breast cancer: interim baseline data from the MADELINE study. Poster presented at the 2018 ESMO Congress; October 2018. Munich, Germany.

Chouaid C, Danson S, Andreas S, Siakpere O, Benjamin L, Ehness R, Dramard-Goasdoue MH, Barth J, Hoffmann H, Potter V, Barlesi F, Price M, Chirila C, Hollis K, Sweeney C, Wolowacz S, Kaye JA, Kontoudis I. Adjuvant treatment patterns and outcomes in patients with stage IB-IIIA non-small cell lung cancer in France, Germany, and the United Kingdom based on the LuCaBIS burden of illness study. Lung Cancer. 2018 Oct;124:310-6. doi: 10.1016/j.lungcan.2018.07.042.

Ritchey ME, Castro C, Buck PM, Fernandez M, Hollis K, Mordin M. A review of 2017 “real-world” evidence literature in Asia. Poster presented at ISPE's 11th Asian Conference on Pharmacoepidemiology; October 2018. Xi’an, China.

Sussman G, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, Grattan C, Hollis K, Hunter S, Knulst A, Lacour JP, Lynde C, Marsland A, McBride D, Maurer M, Nakonechna A, Ortiz De Frutos J, Reynolds M, Sweeney C, Tian H, Weller K, Wolin D, Balp MM. Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: analyses from ASSURE-CSU. Allergy. 2018 Aug;73(8):1724-34. doi: 10.1111/all.13430

Curtis J, Genovese M, Radawski C, Hauber AB, Nowell WB, Hollis K, Gaich C. Patients' perceptions of unmet medical need in rheumatoid arthritis. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 24, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):56. doi: 10.1002/pds.4629

Krueger WS, Young JC, Hollis K, Hauber AB, Gilsenan A, Ritchey ME. Limitations in reporting "benefit-risk" across therapeutic areas in medical device literature. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):515. doi: 10.1002/pds.4629

Ritchey ME, Buck P, Castro C, Fernandez M, Hollis K, Mordin M. "Real-world" evidence for drugs and devices: 2017 literature reviewed. Poster presented at the 34th ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 26, 2018. Prague, Czech Republic. [abstract] Pharmacoepidemiol Drug Saf. 2018 Aug; 27(S2):410-1. doi: 10.1002/pds.4629

Long J, Hunter S, Banerji A, Jain G, Hollis K, Brown TM, Devercelli G, Davis K. Burden of illness in hereditary angioedema: findings from a US patient survey. Presented at the HAE Global Conference 2018; May 18, 2018. Vienna, Austria.

Mordin M, Buck PM, Castro C, Fernandez MM, Hollis KA, Ritchey ME. What does "Real World" evidence mean? A review of 2017 literature. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 22, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S108. doi: 10.1016/j.jval.2018.04.736

Ritchey ME, Hollis KA, Hauber AB, Gilsenan A, Krueger WS. Reporting of "Benefit-Risk" studies for medical devices in published literature. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 23, 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S175. doi: 10.1016/j.jval.2018.04.1167

Hollis K, Proctor C, McBride D, Balp MM, McLeod L, Hunter S, Tian H, Khalil S, Maurer M. Comparison of Urticaria Activity Score over 7 days (UAS7) values obtained from once-daily and twice daily versions: results from the ASSURE-CSU study. Am J Clin Dermatol. 2018 Apr;19(2):267-74. doi: 10.1007/s40257-017-0331-8

Devercelli G, Davis K, Brown M, Hollis K, Hunter S, Long J, Jain G, Banerji A. Burden of hereditary angioedema: findings from a US patient survey. Poster presented at the 2018 AAAAI/WAO Joint Congress; March 3, 2018. Orlando, FL. [abstract] J Allergy Clin Immunol. 2018 Feb; 141(2 Suppl):AB57. doi: 10.1016/j.jaci.2017.12.182

Maurer M, Abuzakouk M, Berard F, Canonica W, Oude Elberink H, Gimenez-Arnau A, Grattan C, Hollis K, Knulst A, Lacour JP, Lynde C, Marsland A, McBride D, Nakonechna A, Ortiz De Frutos J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Wolin D, Balp M-M. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017 Dec;27(12):2005-16. doi: 10.1111/all.13209

Davis KH, Su J, Gonzalez JM, Trudeau JT, Nelson LM, Hauber B, Hollis KA. Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat. Health Qual Life Outcomes. 2017 Oct 16;15(1):201. doi: 10.1186/s12955-017-0780-z

Banerji A, Davis KH, Devercelli G, Hollis K, Hunter S, Jain G. Clinical and demographic characteristics of patients with hereditary angioedema in the United States. Poster presented at the American College of Allergy, Asthma, and Immunology 2017 Annual Scientific Meeting; October 2017. Boston, MA.

Sussman G, Abuzakouk M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Khalil S, Knulst AC, Lacour J-P, Lynde C, Marsland A, Maurer M, McBride D, Nakonechna A, Ortiz de Frutoz FJ, Oude Elberink JNG, Reynolds M, Weller K, Balp M-M. Angioedema in patients with chronic spontaneous urticaria has an additional impact of quality of life but is reported more often by patients than physicians. Presented at the 26th EADV Congress; September 16, 2017. Geneva, Switzerland.

Zografos LJ, Andrews EB, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Petraro P, Djokanovic N, Racanelli VS, Vassilev Z. Evaluating physician knowledge of safety information for aflibercept (Eylea). Poster presented at the 33rd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 30, 2017. Montreal, Canada. [abstract] Pharmacoepidemiol Drug Saf. 2017 Aug; 26(Suppl 2):592. doi: 10.1002/pds

Marsland A, Abuzakouk M, Balp M-M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Hunter S, Khalil S, Knulst AC, Lacour L-P, Lynde C, McBride D, Nakonechna A, Ortiz de Frutoz FJ, Oude Elberink JNG, Sussman G, Tian H, Weller K, Maurer M. Chronic spontaneous/idiopathic urticaria patients with moderate activity have similar burden of disease as those with severe activity - results from the ASSURE-CSU study. Presented at the EAACI Congress 2017; June 20, 2017. Helsinki, Finland.

Gimenez-Arnau A, Abuzakouk M, Balp M-M, Berard F, Canonica GW, Grattan C, Hollis K, Hunter S, Khalil S, Knulst AC, Lacour J-P, Lynde C, Marsland A, McBride D, Nakonechna A, Ortiz de Frutoz FJ, Oude Elberink JNG, Sussman G, Tian H, Weller K, Maurer M. Economic and humanistic burden associated with angioedema in patients with chronic spontaneous/idiopathic urticaria. Poster presented at the EAACI Congress 2017; June 20, 2017. Helsinki, Finland.

McRoy LL, Mitra D, Hollis K, Kaye JA, Zelnak A, Cheryl J. MADELINE: a prospective observational study of mobile-app based patient reported outcomes in advanced breast cancer. Poster presented at the 2016 San Antonio Breast Cancer Symposium; December 9, 2016. San Antonio, TX.

Balp M, Abuzakouk M, Berard F, Canonica GW, Gimenez-Arnau A, Hollis K, Khalil S, Knulst A, Lacour J, Lynde C, Marsland A, Maurer M, McBride D, Nakonechna A, Ortiz de Frutoz FJ, Oude Elberink J, Proctor C, Sussman G, Weller K, Grattan C. Comparison of direct healthcare costs associated with chronic spontaneous/idiopathic urticaria in 7 countries - results from the ASSURE-CSU study. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A565.

Hollis K, Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Khalil S, Knulst AC, Lacour J, Lynde C, Maurer M, McBride D, Nakonechna A, Ortiz De Frutos J, Oude Elberink J, Proctor C, Sussman G, Sweeney C, Tian H, Weller K, Marsland A. Assessing health-utility values for chronic spontaneous/idiopathic urticaria in real-world using the EQ-5D: results from ASSURE-CSU study. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A570-1.

McBride D, Abuzakouk M, Balp M, Berard F, Canonica GW, Gimenez-Arnau A, Grattan C, Hollis K, Khalil S, Knulst A, Lacour J, Lynde C, Marsland A, Nakonechna A, Ortiz de Frutoz FJ, Oude Elberink J, Proctor C, Sussman G, Weller K, Maurer M. Comparative analysis of indirect costs associated with chronic spontaneous/idiopathicurticaria-results from the ASSURE-CSU study in 7 countries. Poster presented at the 2016 ISPOR 19th Annual European Congress; November 1, 2016. Vienna, Austria. [abstract] Value Health. 2016 Nov; 19(7):A573.

White M, Hogue S, Odom D, Cooney D, Bartsch J, Hollis K, Herrem C, Silvia S. EPIPEN4SCHOOLS® survey combined analysis: a comprehensive assessment of anaphylaxis in US schools. Presented at the 2016 AAP National Conference & Exhibition; October 22, 2016. Sacramento, CA.

Proctor C, McBride D, Balp M-M, McLeod L, Hunter S, Tian H, Khalil S, Hollis K, Maurer M. Comparison of twice-daily and once-daily Urticaria Activity Score: results from the first international burden of illness ASSURE-CSU study in inadequately-controlled chronic spontaneous (idiopathic) urticaria. Poster presented at the 25th European Academy of Dermatology and Venereology Congress; September 28, 2016. Vienna, Austria.

White MV, Hogue SL, Odom D, Cooney D, Bartsch J, Goss D, Hollis K, Herrem C, Silvia S. Anaphylaxis in schools: results of the EPIPEN4SCHOOLS survey combined analysis. Pediatr Allergy Immunol Pulmonol. 2016 Sep;29(3):149-54. doi: 10.1089/ped.2016.0675

Zografos LJ, Suzart K, Horvat-Broecker A, Soriano-Gabarro M, Wolin DL, Calingaer B, Davenport EK, Hollis KA, Andrews E. Evaluating physician knowledge of risks and safe use of Xarelto (rivaroxaban). Poster presented at the 32nd ICPE International Conference on Pharmacoepidemiology & Therapeutic Risk Management; August 27, 2016. Dublin, Ireland. [abstract] Pharmacoepidemiol Drug Saf. 2016 Aug; 25(Suppl 3):288-9.

White MV, Silvia S, Hollis K, Goss D, Odom D, Bartsch J, Hogue SL. EPIPEN4SCHOOLS® survey combined analysis: prevalence and triggers of anaphylactic events. Poster presented at the NASN 2016 48th Annual Conference; June 30, 2016. Indianapolis, IN. Previously presented at the 2016 AAAAI Annual Meeting.

Hogue SL, Goss D, Hollis K, Silvia S, White MV. Training and administration of epinephrine auto-injectors for anaphylaxis treatment in US schools: results from the EpiPen4Schools® pilot survey. J Asthma Allergy. 2016 Jun 17;9:109-15. doi: 10.2147/JAA.S106567

White MV, Goss D, Hollis K, Millar K, Silvia S, Siegel PH, Bennett ME, Wooddell MJ, Hogue SL. Anaphylaxis triggers and treatments by grade level and staff training: findings from the EPIPEN4SCHOOLS pilot survey. Pediatr Allergy Immunol Pulmonol. 2016 Jun 16;29(2):80-5. doi: 10.1089/ped.2015.0614